Founded by a group of seasoned healthcare and biotech executives with extensive experiences in research, drug development and commercialization, Bioxodes is developing high value products derived from natural sources established on research conducted by Prof. E. Godfroid (Decrem Y. et al., 2009).
Since 2013, Bioxodes has been developing its lead program based on the Ir-CPI molecule for the prevention of thrombosis. Being the first in a novel class of antithrombotics, Ir-CPI is potentially the world’s first injectable molecule which could be used in all patients groups without causing high levels of bleeding and without needing to be reversed or washed out at the end of critical procedures.
Bioxodes portfolio further includes preclinical drug discovery programs in the areas of cancer, renal and cardiovascular medicine.
Bioxodes owns issued and pending patents related to Ir-CPI in the EU and US. Bioxodes is committed to the ongoing expansion, broadening, and development of its intellectual property portfolio.